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Summary 
Transforming  growth factor Bt  (TGF-/~i) and TGF-/~2 can reversibly inhibit the proliferation 
of hematopoietic progenitor cells in vivo, leading us to hypothesize that such quiescent progenitors 
might be more resistant to high doses ofceU cycle active chemotherapeutic drugs, thereby allowing 
dose intensification of such agents. Initial studies showed that whereas administration of TGF- 
~1 or TGF-B2 did not prevent death in normal mice treated with high doses of 5-fluorouracil 
(5-FU),  those mice that received TGF-~2 did exhibit the beginning of a hematologic recovery 
by day 11 after administration  of 5-FU, and were preferentially rescued by a suboptimal number 
of transplanted bone marrow cells. Subsequently, it was found that the administration  of TGF- 
/32  protected recovering  progenitor cells from  high concentrations  of 5-FU  in  vitro.  This 
protection coincided with the finding that significantly more progenitors for colony-forming 
unit-culture (CFU-c) and CFU-granulocyte, erythroid, megakaryocyte, macrophage (GEMM) 
were removed from S-phase by TGF-/3 in mice undergoing hematopoietic recovery than in normal 
mice. Further studies showed that the administration  of TGF-B protected up to 90% of these 
mice undergoing hematologic recovery from a rechallenge in vivo with high dose 5-FU, while 
survival in mice not given TGF-~ was <40%. Pretreatment of mice with TGF-B1 or TGF-B2 
also protected 70-80% of mice from lethal doses of the noncycle active chemotherapeutic drug, 
doxorubicin hydrochloride (DXR). These results demonstrate that TGF-B can protect mice from 
both the lethal hematopoietic toxicity of 5-FU, as well as the nonhematopoietic toxicity of DXR. 
This report thus shows that a negative  regulator of hematopoiesis  can be successfully  used systemically 
to mediate chemoprotection in vivo. 
M 
Yelosuppression is the dose-limiting  factor for most 
. cancer  chemotherapeutic agents  (1). The resulting 
granulocytopenia  renders many patients  susceptible to op- 
portunistic infections that can be lethal (2). Agents that pro- 
tect the myeloid and lymphoid systems from the suppressive 
effects of radiation or chemotherapy could be beneficial be- 
cause the side effects induced by a standard therapy regimen 
The contents of this publication do not necessarily  reflect  the views or 
policies of  the Department  of  Health  and Human  Services,  nor does  mention 
of  trade  names,  commercial  products, or organizations  imply  endorsement 
by the United States government. 
Animal care  was provided  in accordance  with the procedures  outlined  in 
the "Guide  for the Care  and Use of  Laboratory  Animals"  (NIH  publication 
no. 86-23, 1985). 
might be ameliorated, and the higher doses of therapy that 
could be administered  could result  in increased antitumor 
effacacy (3). Two basic approaches have been envisioned to 
induce chemoprotection. In one approach, positive regulators 
of hematopoiesis, such as IL-1, IL-6, the CSFs, and/or stem 
cell factor could be used to stimulate the proliferation and/or 
production of critical stem, progenitor,  or end-stage hema- 
topoietic cells. This approach could result in a larger pool 
of these cells  before chemotherapy, thus allowing a more rapid 
recovery. Alternatively, they may be used posttreatment to 
restimulate the remains of the stem/progenitor compartment 
after myelosuppression. The validity of this type of approach 
is illustrated by the well-documented  chemoprotective effects 
of IL-1 (4-7). Alternatively the number of critical stem/pro- 
genitor cells could be increased and then a potent negative 
regulator of hematopoiesis used to temporarily inhibit their 
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by cell cycle-active chemotherapeutic drugs. Several cytokines, 
including TGF-~, have been demonstrated to be potent nega- 
tive regulators of hematopoiesis (8-12). 
TGF-B is a 25-kD homodimeric member of a functionally 
related family of polypeptide growth factors  that show di- 
verse effects on growth and cell development (13-16). TGF-B 
exists in at least five isoforms (17), which exhibit 70-80% 
sequence  identity (14). TGF-3I  and/or TGF-fl2  have been 
shown to preferentially inhibit the proliferation and differen- 
tiation of early routine and human hematopoietic progen- 
itors both in vitro and in vivo (18-25). Such cell cycle--arrested 
progenitors could be more resistant to cycle-active chemother- 
apeutic drugs, thereby allowing a dose intensification of such 
agents. 
In this report we demonstrate that in vivo treatment with 
TGF-B1  or TGF-/32 protects  some  of the progenitors for 
CFU-culture (CFU-c) 1, CFU-granulocyte, erythroid, mega- 
karyocyte, macrophage (CFU-GEMM) and high prolifera- 
tive potential- colony forming cells (HPP-CFC) in normal 
and hyperproliferative marrow from the toxicity of 5-fluoro- 
uracil (5-FU), thereby resulting in an ability to successfully 
dose intensify 5-FU. We also report that recombinant r)TGF-3 
is effective in vivo in protecting mice from acutely toxic doses 
of doxorubicin hydrochloride (DXR),  through effects that 
are  at  least  partially nonhematological.  This  report  thus 
demonstrates that negative regulation of hematopoiesis can 
be successfully exploited for dose intensification of chemo- 
therapy. 
Materials and Methods 
Mice.  Specific  pathogen-flee BALB/c mice at 8-12 wk of age 
were obtained from the animal production facility of the National 
Cancer  Institute-Frederick  Cancer  Research and  Development 
Center (Frederick, MD). 
Growth Factors and Reagents.  The rTGF-BI was a generous gift 
from Dr. M. Palladino,  Jr. (Genentech Inc., San Francisco, CA). 
The rTGF-fi2 was produced in Chinese hamster ovary cells and 
generously supplied by Celtrix Pharmaceuticals  (Santa Clara, CA). 
For injection, the TGF-/3I was diluted in HBSS +  0.1% normal 
mouse serum (NMS) and TGF-32 in citrate buffer (pH 6.0) con- 
taining  1% NMS. TGF-~I or TGF-32 were administered intra- 
peritoneally according to various protocols outlined in the figure 
legends.  Recombinant  murine  IL-3 and  recombinant  human 
erythropoietin (rhEpo) were purchased from PeproTech, Inc. (Rocky 
Hill, NJ), and Amgen Biologicals (Thousand Oaks, CA), respec- 
tively. 5-FU (LymphMed, Rosemont, IL) was diluted in sterile dis- 
tilled water and administered intravenously to the mice at the indi- 
cated doses while DXR (Sigma Chemical Co., St. Louis, MO) was 
diluted in HBSS immediately before intraperitoneal injection. 
CFU-c and CFU-GEMMAssay.  BM cells were aspirated from 
the paired femurs and tibias of control or experimental mice with 
1  Abbreviations used in this paper: BMT, BM transplant; CFU-c, CFU- 
culture; CFU-GEMM, CFU-granulocyte, erythroid, megakaryocyte, 
macrophage; DXR, doxorubicin  hydrochloride;  Epo, erythropoietin;  5- 
FU, 5-fluorouracil;  HPP-CFC, high-proliferative  potential-colony-forming 
cell; NMS, normal mouse serum; r, recombinant. 
cold HBSS without Ca  ~+  and Mg  2.  (washing buffer), washed 
twice, and resuspended  in ce medium (GIBCO BRL, Gaithersburg, 
MD) that was supplemented  with 20% FCS (Biofluids,  Inc., Rock- 
ville, MD), 2 x  10 -4 mol/liter hemin (Sigma Chemical Co.), 5 x 
10 -s mol/liter 2-mercaptoethanol (Sigma Chemical Co.), 8 U/ml 
Epo, 100 U/ml rhlL-3, and 0.05 mg/ml gentamicin in 0.35% Sea- 
plaque agarose (FMC Bioproducts, Rockland, ME). 10  s BM cells 
in 1 ml of this medium were plated in 35-ram Lux petri dishes 
(Miles Laboratories, Inc., Naperville, IL) and incubated at 37~ 
in 5% CO2 for 10 d at which time the number of colonies was 
determined. Multipotential colonies  containing granulocyte,  eryth- 
roid, megakaryocyte  and macrophage  lineages were scored  as CFU- 
GEMM, while monocyte (CFU-M), myeloid (CFU-G), erythroid 
(CFU-e, BFU-e), and myelomonocytic  (CFU-GM) colonies were 
designed as CFU-c (26). Data are presented as the total number 
of CFU obtained from the paired femurs and tibias of each mouse. 
HPP-CFC Assay.  HPP-CFC were detected using a modified 
double-layer  agar technique (27). Briefly,  lower layers (0.5% agarose 
in c~ medium/20% FCS containing hemin, IL-3, 1I,-1, and super- 
natant from L929 cells [source of CSF-1]) were prepared in 35-ram 
Lux petri  dishes, and 2-8  x  104 cells in 0.35%  agarose in ce 
medium/20% FCS was added  as a second  layer.  Cultures  were scored 
after  incubation  for  14  d  under  low  oxygen  tension  (7.5% 
05/7.5% CO2/85%  N2). All colonies with a diameter >0.5 mm 
were scored as HPP-CFC. 
Thymidine Suicide Assay.  The proliferative  status of  various he- 
matopoietic  progenitors was measured  by calculating  the percentage 
of CFU-c  and  CFU-GEMM  remaining after incubation with 
methyl[3H]thymidine (37.0 MBq/ml,  sp  act  925  GBq/mmol) 
(Amersham Corp., Arlington Heights, IL) as previously  described 
(28, 29). BM cells  were resuspended  in culture medium (oe medium/ 
20% FCS) at a concentration of 2  x  106 cells/ml and incubated 
with 100/zCi/ml  of [3H]TdR for 30 rain at 37~  The incuba- 
tion was terminated by placing the cell suspensions on ice. CFU-c 
and CFU-GEMM assays  were initiated immediately after washing 
the cells twice with cold thymidine at 100 #g/ml and plating was 
done in cold thymidine at 10 #g/ml. 
Statistical Analysis.  All statistical evaluations were performed 
using computer software; Instat version 2.02 or GraphPad Prisma 
version 1.0 (GraphPad Software, San Diego, CA). The significance 
of the differences  between groups was evaluated  by analysis  of vari- 
ance followed by two-tailed Student's t test. A two-way analysis 
of  variance test was used to determine statistical  significance  of treat- 
ment on cell cycle. Results from survival experiments were ana- 
lyzed using a log-rank nonparametric test and expressed as Kaplan- 
Meier survival curves. 
Results 
Pretreatment with rTGF-fl~ In Vivo Delays Progenitor Recovery 
in Mice Subsequently Treated with a Sublethal Dose of  5-FU.  The 
results presented in Fig. I demonstrate that although pretreat- 
ment with rTGF-/31 initially decreased the formation of all 
progenitors by day 9 after injection with a sublethal dose of 
5-FU,  the later recovery that occurs  by the end of the re- 
bound phase  (days 13-15)  exceeded the rebound levels ob- 
served  for mice that received  only 5-FU.  This effect was 
significant at the p (0.001 level for both CFU-c and HPP- 
CFC, with CFU-GEMM numbers also showing a trend to- 
ward an increase. 
Pretreatment of Normal Mice with TGF-fll and TGF-fl2 Does 
1048  rTGF-fll  and 3-2 Protect Mice from In Vivo 5-Fluorouracil  and Doxorubicin :::b J: 
U.P" 
6O 
CFU-c 
50 
40 
~-  5-FU 
30  -e- TGFgI+5_FU 
20 
10 
3  4  5  6  7 
T 
/  ~J 
// 
/ 
8  9  10  11  12  13  14  15  16 
o 
:S 
s; 
uJ 
? 
u. 
0 
Day after 5-FU treatment 
4000 
CFU-GEMM 
3000  I 
~-  5-FU  I 
2000  ~-  TGFB,+5-FU 
1000 
3  4  5  6  7  8  9  10  11  12  13  14  15  16 
16 
14 
12 
~  10 
""  4 
2 
0  ~ 
2 
Day after 5-FU treatment 
HPP-CFU  T 
-~  5-FU 
TGFRt+S.FU 
/ 
3  4  5  6  7  8  9  10  11  12  13  14 
Day after 5-FU treatment 
Fig, re  1.  Effect of pretreatment  with  rTGF-/~I on  5-FU-induced 
recovery of myeloid cells. Mice (n  =  10) were injected intraperitoneally 
with HBSS + 0.1% NMS or 2.5/~g rTGF-/~I twice daily on days -4-0. 
On day 0, all mice were injected intravenously with 5-FU (150 mg/kg). 
Groups of mice were killed at various times thereafter, BM collected, and 
colony assays performed. The data are presented as the mean +  SD for 
three replicates  of a pooled cell  population, and the total CFU/mouse (total 
CFU from paired femurs and tibias) was calculated based on their fre- 
quency multiplied by the total cellularity per mouse. 
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Figure 2.  Effect of rTGF-/~I and  rTGF-/~2 pretreatment  on  5-FU- 
induced lethality. A shows an experiment where mice (n  =  10) were in- 
jected intraperitoneally twice a day for 5 d consecutively  with the previ- 
ously established optimal dose of rTGF-31 (2.5/xg/dose) or with diluent 
(HBSS +  0.1% NMS). 1-2 h after the last injection of rTGF-/~I, mice 
were injected with high sublethal (200 or 250 mg/kg) doses of 5-FU. 
B shows an experiment  where mice (n = 10) were injected  intraperitoneally 
with various dilutions of rTGF-B2 (0.01-0.25/~g/dose) diluted in citrate 
buffer. Control mice were injected with diluent only. 1-2 h after last in- 
jection of rTGF-32 mice were injected with a lethal dose (340 mg/kg) 
of 5-FU. All mice were then monitored for toxicity and survival. 
Not Protect Mice against Lethal Doses of S-FU.  Because of the 
enhanced late  hematopoietic  recovery noted in  the results 
presented in Fig. 1, we speculated that rTGF-/~ pretreatment 
might protect enough CFU progenitors from the toxic effects 
of higher doses of 5-FU that  these mice might  survive an 
otherwise lethal injection of 5-FU. However, mice that were 
pretreated twice daily with  TGF-B1 (2.5  /zg/dose) for 5 d 
consecutively were actually less resistant to high doses of 5-FU 
(200 mg/kg 5-FU [LD10] vs. TGF-B1  +  200 mg/kg 5-FU 
[LD60], p  <0.01,  and 250 mg/kg  5-FU [LD60]  vs. TGF-31 
+  250 mg/kg  5-FU [LD100], p  <0.01;  Fig.  2 A). Pretreat- 
ment with TGF-B2 also was found to potentiate the toxicity 
of high (340 mg/kg)  dose [LD70]  5-FU such that no mice 
survived (Fig.  2 B).  Lower daily doses of TGF-B2 did not 
potentiate 5-FU-induced  toxicity, but  neither was  protec- 
tion induced.  A  series of additional studies using pretreat- 
ment with either TGF-/~I or TGF-/~2 demonstrated only in- 
creased toxicity, not  protection  (data  not  shown). 
Reversal of TGF-,81-potentiated 5-FU-induced Toxicity by BM 
Transplant (BMT).  Myelotoxicity as the cause of death in 
mice  treated  with  TGF-/~I  and  5-FU  was  confirmed  by 
pretreating mice with TGF-B1 for 5 d  consecutively before 
a bolus injection of high dose (250 mg/kg) 5-FU [LDs0]  on 
day 0 and subsequent syngeneic BMT (107 cells) on days 2, 
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Figure  3.  Effect of BM  transfer  on  survival of mice  treated with 
rTGF-B1 and a high sublethal dose of 5-FU. Mice (n =  10) were injected 
intraperitoneally with (2.5/zg/dose) or rTGF-B~  for 5 d consecutively fol- 
lowed by a bolus injection  of 5-FU (250 mg/kg) 2 h after the last injection 
of rTGF-/~t. On days 2, 3, and 4 some mice were given intravenous syn- 
geneic  BMT (107 cells). All mice were then monitored for toxicity and 
survival. 
3, and 4 (Fig. 3). As expected from the data shown previ- 
ously in Fig. 2, none of the mice treated with both TGF-/31 
and 5-FU survived (5-FU alone [LDs0] vs. TGF-B1 +  5-FU 
[LD100], iv <0.01).  However, 80% of the mice treated with 
TGF-~St and 5-FU followed by BMT survived (TGF-~St + 
5-FU [LD100] vs. TGF-B1 +  5-FU  +  BMT [LD20] iv <0.01), 
confirming  that the increased toxicity of 5-FU by TGF-~81 
was predominantly  hematologic. 
TGF-~ Protects Some Progenitors and Mature Myeloid Cells 
from High Doses of5-FU.  As previously noted,  mice that 
were pretreated with TGF-B2 for 5 d consecutively exhibited 
an enhanced toxicity  (LD100 0.25  #g/dose and LDs0 at 0.1 
#g/dose  of TGF-B2) after high  dose  (340  mg/kg)  5-FU 
[LD60]. However, analysis of progenitor levels (Fig. 4, A  and 
B) revealed a significant ~  <0.001) increase in the number 
of CFU-GEMM and CFU-c on days 7 and 11 in mice pre- 
treated daily with 0.25/zg  of TGF-B2 as compared with 
mice treated only with 5-FU (CFU-GEMM at day 7: 4-fold 
increase, p <0.001, and at day 11: 7.5-fold increase, iv <0.001; 
and CFU-c at day 7: 3-fold increase, iv <0.001,  and at day 
11: 12-fold increase, iv <0.001). Furthermore, the lower daily 
dose of TGF-B2 (0.1 /zg), while less efficient than a higher 
dose (0.25  #g) in facilitating the recovery of CFU-c at an 
earlier time point (day 7:280  +  8 vs. 620  _+  13), was equally 
effective to the higher dose in enhancing CFU-c at a later 
time point (day 11:5010  +  322 vs. 5365  _+ 209). The 0.1/~g 
daily dose also was efficient in protecting  CFU-GEMM on 
day 11 as compared with mice treated only with 5-FU (185 
_+  19 vs. 40  +  3, p <0.001).  This recovery of CFU by day 
11  in TGF-/32-pretreated mice  was  substantial in that the 
number of CFU-c was "~30% of normal for either dose of 
TGF-i52, whereas the number of CFU-GEMM was 29 and 
18% of normal for TGF-152 doses of 0.25 and 0.1 #g, respec- 
tively. These levels of CFU-c and CFU-GEMM were 12-fold 
and 7.5-fold,  respectively, higher in the TGF-AS-pretreated 
mice than in those that only received 5-FU. Similarly, an anal- 
ysis  of total  BM  cellularity  (Fig.  4  C)  showed  that mice 
pretreated with TGF-B2 exhibited some rebound by day 11 
(1.5  x  106 and 1.6  x  106 cells) when given daily TGF-~2 
doses of 0.25 and 0.1 #g, respectively, as compared with 0.4 
x  106 cells in mice  treated only with 5-FU. 
Mice That Are Pretreated with TGF-fl2 before High  Dose 
5-FU Are More Easily Reconstituted with BM Cells Than Mice 
Only Given 5-FU.  The results presented in Fig. 4 demon- 
strate that pretreatment with TGF-i5 did protect some pro- 
genitors, suggesting  such protection did not translate to ex- 
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Figure  4.  Effect  of pretreatment  with rTGF-/~2 on progenitors  in mice subsequently  treated with a lethal dose  (340 mg/kg) of 5-FU. Mice (n  = 
10) were injected  intraperitoneally  with 0.25 or 0.1/zg of rTGF-/52 twice daily on days -4-0. On day 0, 2 h after the last injection  of rTGF-/~2, all 
mice were injected intravenously  with 5-FU. Groups of mice were killed and BM was obtained  at various times after the injection of 5-FU. The total 
number of BM cells obtained  from the paired femurs and tibias of each mouse was determined  before the colony assay was performed and read on 
day 14. The data are presented as the mean  _+ SD for three replicates of a pooled cell population  and the total CFU/mouse was calculated based on 
their frequency multiplied by the total  cellularity  per mouse. 
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Figure  5.  Effect of BMT on survival of mice treated 
with rTGF-32 and a lethal dose of 5-FU.  Mice (n  =  10) 
were  injected  intraperitoneally  with  (0.1 #g/dose)  of 
rTGF-/~2 or diluent  for 5 d consecutively  followed by a 
bolus  injection of 5-FU (340 mg/kg) 2 h after the last 
injection of rTGF-/~2. On days 1, 3, 6, and 9 some mice 
were given an  intravenous  transfer  with  a suboptimal 
number (106) of syngeneic BM calls. All mice were then 
monitored for toxicity and  survival 
tended survival, because the number of progenitors protected 
fell below a critical threshold. To test this hypothesis, mice 
were treated with TGF-32 (0.1 gig/dose) or vehicle control 
(citrate buffer) for 5 d consecutively followed by a bolus in- 
jection  of  an  acutely  lethal  [LDs0] dose  of  5-FU  (340 
mg/kg). Some mice then received a suboptimal BMT (10  6) 
on days 1, 3, 6, and 9 (Fig. 5). Reconstitution of mice treated 
only  with  5-FU  [LDs0] by  suboptimal  BMT  did  not 
significantly increase in survival [LD60] (p >0.1), whereas the 
group that had been pretreated with TGF-~2 before 5-FU 
[LDg0] exhibited a significantly improved (p <0.001)  survival 
of 90%  [LDt0] after  suboptimal BMT. 
In Vivo Administration of TGF-fll or TGF-fl2 Protects Regen- 
erating Progenitor Cells from 5-FU In Vitro.  The results pre- 
sented in Figs.  1, 4, and 5 demonstrate that TGF-3 spares 
some critical short-term repopulating progenitors in mice from 
the acutely toxic effects of 5-FU, suggesting that these cells 
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are more resistant to direct killing by 5-FU. This hypothesis 
was confirmed by treating mice with rTGF-3t (2.5/zg/mouse 
twice daily) (experiment 1) or rTGF-/~2 (0.1/~g/mouse once 
a day) (experiment 2) on days 7-11 of the subsequent hyper- 
proliferative recovery phase that follows a sublethal dose (150 
mg/kg) of 5-FU.  Progenitors for CFU-c  (Fig.  6 A)  and 
CFU-GEMM (Fig. 6 B) obtained from mice that had received 
rTGF-3t or TGF-32  in addition to 5-FU were more resis- 
tant to the direct toxic effects of 5-FU in vitro. Specifically 
the percent decrease in total CFU-c number after exposure 
to 10/~g/ml or 25/zg/ml 5-FU in vitro was 70 and 93%, 
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Figure  6.  Effect of rTGF-Bt and 
rTGF-•2  administration  in vivo on 
subsequent sensitivity of progenitor 
cells to 5-FU in vitro. Mice (n  = 
5) were injected  intravenously  on 
day 0 with  150 mg/kg of 5-FU. 
In experiment  1,  some  mice  re- 
ceived 2.5/~g/mouse of rTGF-31, 
whereas in experiment 2, some mice 
received 0.1/~g/mouse of rTGF-B2, 
twice daily on days 7-11 and once 
in the morning of day 12. 2 h after 
the last injection of rTGF-3, all mice 
were killed and the BM was har- 
vested.  BM  samples  from  each 
group were then treated for 2 h in 
vitro with media only, 10/~g/ml of 
5-FU and 25/~g/ml of 5-FU. The 
cells were then washed, recounted, 
and  plated  in triplicate  for CFU- 
formation. The data are presented 
as the mean  +  SD for three repli- 
cates of a pooled cell population and 
the total CFU/mouse was  calcu- 
lated based on obtained frequency 
multiplied by the total cellularity 
per mouse obtained  after in vitro 
treatment. 
1051  Grzegorzewski et al. Table  1.  Effect  of rTGF-~2 Administration  In  Vivo  on Subsequent Sensitivity  of HPP-CFC Progenitor Cells to 5-FU In  Vitro 
Percent decrease 
Number of  from control  Fold increase 
In vivo  HPP-CFC  mice (media  in HPP-CFC 
treatment  In vitro treatment  recovered  only)  formation* 
5-FU 
5-FU rTGF-/~2 
Media only  576  _+  77  N/A*  N/A 
5-FU (10 #g/ml)  132  +  46  77  N/A 
5-FU (25  /~g/ml)  115  _+  40  80  N/A 
Media only  682  +  48  N/A  0.2 
5-FU (10 #g/ml)  544  _+  91  20  3.1 
5-FU (25  #g/ml)  398  _+  99  42  2.5 
Mice (n  =  5) were injected intravenously on day 0 with 150 mg/kg of 5-FU. Mice received 0.1 /xg of rTGF-B2, BID on days 7-11,  and once 
on the morning  of day 12. 2 h after the last injection of rTGF-32, all mice were killed and the BM cells were harvested. BM samples from each 
group were then  treated for 2 h in vitro with media only,  10/.tg/ml of 5-FU, and 25 /zg/ml of 5-FU.  The cells were then washed, recounted, 
and plated in triplicate for HPP-CFC formation.  The data are presented as the mean _+  SD for three replicates of a pooled cell population and the 
total CFU/mouse was calculated based on obtained frequency multiplied by the total cellularity per paired femurs and tibias obtained after in vitro 
treatment.  This is a representative experiment  of two performed. 
* Value indicates fold increase in HPP-CFC formation in mice treated in vivo with 5-FU (150 mg/kg) and rTGF-B2 compared with 5-FU alone. 
* N/A, not applicable. 
respectively, in mice that had not received rTGF-31 in vivo, 
but only 30 and 61%, respectively, in those that had received 
rTGF-31. Mice receiving TGF-~2 also were more resistant to 
5-FU  in  vitro  (23  and  67%  decrease  at  doses  of  10  and 
25/zg/ml) as compared with a decrease of 57 and 82%  for 
mice that had not received TGF-32. Similar effects were ob- 
served  for  both  TGF-B1  and  TGF-32  on  progenitors  for 
CFU-GEMM. 
In  addition,  mice  that  received  5-FU  plus  TGF-31  or 
TGF-B2 exhibited a considerably greater number of all types 
of CFU at the time of marrow harvest on day 12 than did 
mice that received only 5-FU.  This effect, combined with 
the enhanced resistance to 5-FU in vitro, resulted in a 3.7- 
fold (TGF-31) and 1.5-fold (TGF-32) increase in the number 
of CFU-c and a 2.7-fold (TGF-3t) and 3.1-fold (TGF-32) in- 
crease in the number  of CFU-GEMM  that remained after 
Table  2.  Effects of rTGF-~2 on Cycling  of Progenitor Cells in Mice Previously Treated with a Sublethal Dose of 5-FU 
Percent reduction 
Progenitor  Experimental  Total no. of progenitor  in S-phase cells 
type  treatment  cells in S-phase  by TGF32 
CFU-c 
CFU-GEMM 
5-FU  19,787  - 
5-FU  +  TGFfl2  400  >99 
Diluent  11,836  - 
Diluent  +  TGF~2  8,433  29 
5-FU  4,667  - 
5-FU  +  TGF32  1,467  69 
Diluent  1,563  - 
Diluent  +  TGF32  613  61 
Donor mice (n  =  3) were injected intravenously with 5-FU (150 mg/kg). From day 9 to 13 mice were treated intraperitoneally with rTGF-fl2 
(0.1/~g/dose)  or citrate buffer (diluent). 2 h after the last injection of rTGF-32, all mice were killed and BM cells were harvested. For cell cycling 
analysis of various progenitors, BM cells (2  x  106/ml) were cultured in the presence of [3HITdR (100 #Ci/ml) or (cold) TdR (control) for 30 min 
at 37~  After treatment, BM cells (10  s) were plated for colony forming assays. The total number of progenitor  cells in S-phase was calculated 
by subtracting the mean number of colonies obtained after in vitro treatment  with [3H]TdR from those treated with (cold) TdR, and multiplied 
by the total cellularity of paired donors'  femurs and tibias. 
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5-FU plus TGF-3 vs. 5-FU alone, with similar effects noted 
at an in vitro concentration of 25/~g/ml 5-FU for TGF-/3t 
or TGF-32. This protection by TGF-3 also extends to the 
more primitive HPP-CFC progenitors since the number sur- 
viving after exposure to 10/zg/ml or 25/zg/ml 5-FU in vitro 
was increased 4.1-fold and 3.5-fold, respectively, in mice that 
had received TGF-3z in vivo as compared with those that 
did not receive TGF-~2 (Table 1). These results demonstrate 
that TGF-/3 renders various progenitor cells more resistant 
to direct killing by 5-FU. 
Treatment of Mice with TGF-~2 during the Post-5FU Hyper- 
proliferative Phase Decreases Cycling of CFU Progenitors.  The 
experiment shown in  Table 2  demonstrates  that  TGF-/32 
treatment during the hyperproliferative phase of hematologic 
recovery after 150 mg/kg 5-FU reduces the total number of 
CFU-c progenitors in S-phase  by 19,387 (>99%) and thereby 
protects them from killing by high sp act radioactive thymi- 
dine. In contrast, in normal mice, which have fewer total 
CFU-c progenitors in S-phase, the administration of TGF-/3z 
reduces the total number of CFU-c in S-phase by 3,403, or 
only 29%. The resuhs for CFU-GEMM progenitors were 
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Figure 7.  Effect  of rTGF-32 administered during 
the late hyperproliferative phase of mice rendered 
leukopenic by 5-FU on subsequent  sensitivity of 
progenitor cells to 5-FU in vivo. Mice (n  =  10) 
were injected  intravenously  on day 0  with  150 
mg/kg of 5-FU. On days 9-13, mice were treated 
twice a day with rTGF-/32 (0.1/*g/dose)  or with 
diluent  only. On day 13, 2 h after last injection, 
a second high dose of 5-FU (.4,300 mg/kg; or 
B, 360 mg/kg) were administered.  All mice were 
then monitored for toxicity and  survival. similar with TGF-~2 reducing the total number by 3,200 in  100 
mice recovering from 5-FU, but only by 950 in normal mice  90 
<001)  .0 
Treatment of Mice with TGF-fl2 during the 5-FU-induced  70 
Bone Marrow Hyperproliferative  Phase  Protects  Against High Doses  "~  >  60 
of 5-FU.  Because TGF-~ protects recovering marrow pro-  "~.  50 
genitor cells  from both  5-FU  and  [3H]thymidine, studies  ~  40 
were performed to determine whether mice could be pro- 
tected against a subsequent higher dose of 5-FU in vivo. There-  SO 
fore, TGF-32 was administered on days 9-13 (late recovery  20 
phase) after initial exposure to 150 mg/kg 5-FU, and these  10 
mice were then rechallenged with high doses (300  or 360  0 
mg/kg) of 5-FU (Fig. 7). Mice pretreated with low dose 5-FU 
plus TGF-3a, followed by high doses of 5-FU (300 mg/kg 
[LD60]) (Fig.  7 A)  and 360  mg/kg  [LDg0] (Fig.  7 B)  ex- 
hibited an increased survival rate of 90%, p <0.05 and 60%, 
p  <0.05,  respectively, as compared with the mice that did  1  oo 
not receive the TGF-/~2 treatment (Fig.  7, A  and B).  This  90 
protective effect was lost if the TGF-B2 was administered on  80 
days 5-8 (early recovery phase) after 150 mg/kg 5-FU (data  70 
m 
not shown),  m  >  60 
TGF-~z and TGF-~2 Protect Mice against Lethal Doses of  ";.  sO 
DXR.  The effects of rTGF-3 on lethality induced by high  ~  40 
doses of the anthracycline chemotherapeutic drug DXR also 
were studied. Surprisingly, as the data from a representative  30 
experiment show, pretreatment with TGF-31 (Fig.  8 A) or  20 
TGF-32 (Fig.  8 B) for 4 d protected mice in a dose-depen-  10 
dent manner from an acutely lethal dose (16 mg/kg) of DXR  0 
(TGF-31:2.5  #g/day,  80%  survival,  p  <0.01;  TGF-31: 
0.5/~g  twice daily, 20%  survival,  p  <~0.01; and TGF-32: 
0.5 #g twice daily,  70%  survival, p  <~0.01). Because DXR 
is only moderately myelosuppressive in mice, we also inves- 
tigated whether the mechanism of TGF-3-mediated protec- 
tion was exclusively hematopoietic (Fig. 8 C). It is interesting 
to note that the mortality of mice treated with a lethal dose 
of DXR was not reversed by a subsequent BM transfer (107 
cells injected 24 h  after DXR  administration),  suggesting  "~  > 
that the mechanism of TGF-3 protection is at least partially  "~; 
nonhematopoietic,  t~ 
Discussion 
Myelosuppression is a major dose-limiting toxicity of many 
widely used cancer chemotherapeutic drugs (1, 2). Both posi- 
tive and negative regulators of hematopoiesis have been pro- 
posed as potential chemoprotective agents (12). Positive regu- 
lators of hematopoiesis (e.g., CSFs, IL-1, Epo, and stem cell 
factor) are known to be useful in this regard (9,  12), while 
the application of negative regulators (e.g., TGF-3) of he- 
matopoiesis as potential protective agents is not yet dear (30). 
Negative regulators might temporarily protect vital hemato- 
poietic stem/progenitor cells in the BM by inhibiting their 
ability to cycle during and shortly after the delivery of che- 
motherapy thereby allowing either acute or chronic dose in- 
tensification (31). This hypothesis is supported by reports that 
TGF-3s can reversibly inhibit the proliferation of CFU-S (25) 
and primitive hematopoietic progenitors in vitro (32),  and 
arrest a variety of cells in middle to late G1 phase of the cell 
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Figure  8.  Chemoprotective  effects  of rTGF-31 and TGF-32 for DXR. 
Groups of mice (n = 10) were injected  intraperitoneally  twice a day for 
days: -4-0 with various doses of rTGF-31 (.4, 0.5-2.5 #g/dose) or 
rTGF-32 (B,  0.1-0.5 #g/dose). Control groups were injected with 
diluents. 1-2 h after the last TGF-3 injection mice  were challenged  with 
a single intraperitoneal  injection (14 mg/kg) of DXR. Additionally  mice 
injected with DXR only were also given a single injection of BM cells 
(107) (C). All mice were then monitored for toxicity and survival. 
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stems from observations that TGF-~I in the BM microen- 
vironment may play a role in the regulation of hematopoiesis 
(36), TGF-/31 and TGF-B2 potently inhibit the proliferation 
of routine progenitor cells (11, 19), and that TGF-Bs syner- 
gize in vitro with GM-CSF to increase murine granulopoi- 
esis (36) and the number of CFU-GM (37, 38). Overall, these 
findings suggest that TGF-~s alter  both proliferation and 
differentiation of hematopoietic progenitor cells. 
The present studies were initiated to determine whether 
transient inhibition of CFU progenitor proliferation by TGF-~ 
could be exploited to protect bone marrow stem/progenitor 
cells from destruction by chemotherapeutic drugs, thereby 
allowing dose intensification of chemotherapy. Initial experi- 
ments confirmed that  pretreatment with TGF-~I  poten- 
tiated the rebound that follows administration of 150 mg/kg 
5-FU, a regimen widely used to increase the number of cy- 
cling progenitor cells (39-42).  However, there was also an 
initial delay in hematopoietic recovery of TGF-~/-pretreated 
mice suggesting a lower proliferative  response of any pro- 
tected stem/progenitor cells to the positive regulatory signals 
that are produced physiologically in response to myelosup- 
pression. This effect could be due to an inhibition by TGF-~ 
of stem/progenitor cell entry into cell cycle. This point may 
be important since stem and progenitor cells are heteroge- 
neous, with some in Go,  some slowly entering the cycle 
(long lag of G1 phase),  and some in cycle (43). Despite the 
early inhibitory effect of rTGF-~I on hematopoietic progen- 
itors, the later enhanced effect suggests that the apparent in- 
hibition of proliferation also resulted in protection of some 
progenitors from 5-FU-mediated toxicity. 
In spite of the ability of TGF-~/to allow an enhanced re- 
bound  after  5-FU,  pretreatment  with  either  TGF-B1 or 
TGF-/~2 failed to protect normal mice against high sublethal 
or lethal doses of 5-FU, and actually rendered them more 
susceptible to lethality by 5-FU. This increased toxicity was 
hematological since subsequent BM transfer largely reversed 
the effect, suggesting that temporary inhibition of the func- 
tion of a critical short-term repopulating subset of progen- 
itor cells might prevent a timely recovery in 5-FU-treated 
mice, allowing the development of septicemia and death from 
infection. This hypothesis was supported by data showing 
that there was a significant increase in the number of total 
BM cells, CFU-c, and CFU-GEMM in mice treated with 
TGF-B plus high dose 5-FU vs. those treated with high dose 
5-FU alone, although all mice in both groups died by around 
day 15. Hematologic protection by TGF-3 was confirmed 
when mice pretreated with TGF-3z before high dose 5-FU 
(340 mg/kg) were salvaged by a suboptimal number of bone 
marrow cells, suggesting that TGF-3 did protect some pro- 
genitors from 5-FU-induced toxicity in normal mice, but 
their number and/or function was inadequate to completely 
protect mice during the critical time period when septicemia 
develops. 
It is important to note that TGF-3 does not potentiate 
the cell cycle-dependent toxic effects of 5-FU since progen- 
itor cells obtained from mice given a sublethal dose of 5-FU 
followed by TGF-3 were more abundant and more resistant 
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to in vitro treatment with increasing doses of 5-FU. Thus, 
TGF-/~ altered the number of BM progenitors, and also their 
physiological status, suggesting that the effectiveness  of TGF-B 
as a chemoprotective agent might be at least partially depen- 
dent on the cycling status of progenitors. This was confirmed 
by studies showing that TGF-/~ treatment dramatically re- 
duced  the  number  of CFU  progenitors  in  S-phase  and 
prevented their killing by high sp act  [3H]thymidine, an 
effect that has been reported by Cashman et al. (32) in vitro 
for human progenitors in long-term culture-adherent assays, 
and by Migdalska et al. (25) for in vivo treatment of recovering 
marrow in mice. This effect was significantly more pronounced 
in mice recovering from 5-FU than in normal mice, and was 
greater for CFU-c than CFU-GEMM progenitors, supporting 
the hypothesis that the protection of the mature progenitors 
is especially critical for protection during the critical 7-10-d 
period after subsequent exposure to high dose 5-FU. These 
results speak most directly to protection of short-term marrow 
repopulating activity (STMRA). However, the survival curves 
do extend to 200 d (Fig.  7 B) suggesting that such protec- 
tion also extends to the long-term marrow repopulating cells 
(LTMRC) reportedly spared by 5-FU (44). 
Thus, protection of existing progenitors in normal mice 
by TGF-3 is not sufficient and there is a requirement for an 
increased number of progenitors for successful chemoprotec- 
tion. For optimal protection against cycle-dependent chemo- 
therapeutic agents, stem/progenitor cells needed to be posi- 
tively stimulated (e.g., with a low sublethal dose of 5-FU) 
to cause an increase in proliferation before exposure to TGF-3. 
Therefore, more progenitors are cycle-arrested by TGF-3, and 
more can quickly reenter cycle after administration of cell 
cycle-dependent chemotherapeutic agents. 
DXR  is  a DNA  intercalating agent that blocks topo- 
isomerase II and is myelosuppressive in humans (1, 45).  In 
confirmation of our earlier preliminary findings (46), we have 
shown that, unlike for 5-FU, the repeated preadministration 
of TGF-~I or TGF-32 to unstimulated mice protects some 
mice from lethal doses of DXR.  Although myelosuppres- 
sion is one of the dose-limiting toxicities associated with the 
clinical use of DXR, cardio- and intestinal toxicity are also 
evident (47,  48),  whereas liver tissue is relatively resistant 
(47). In mice, the cardioprotective drug ICRF-187 (ADtL- 
529) is able to decrease DXR-related toxicity in mice (49). 
TGF-/~I also  has  been found to  ameliorate TNF-induced 
cardiotoxicity when given before or immediately after isch- 
emic injury (50), and to inhibit the proliferation of intestinal 
epithelial cells suggesting that it might protect against cell 
cycle--dependent gut toxicity of DXR (25, 48). In our studies, 
the acutely toxic effects of DXtL in mice were not reversed 
by BMT suggesting that TGF-3-mediated protection against 
DXIL is at least  partially nonhematologic. Thus, the cell 
cycle-dependent protective effects of TGF-3s are not limited 
to the hematopoietic system since TGF-33 has been shown 
to decrease proliferation of epithelial cells thereby decreasing 
5-FU-induced mucositis (51). 
In summary, we have demonstrated that TGF-3 can pro- 
tect mice against lethal doses of 5-FU and DXR.  TGF-/33 
has been reported to also protect against in vitro toxicity by 4-hydroxycyclophosphamide  (52),  and  TGF-fl2  may-have 
some protective effects against cyclophosphamide in vivo (46). 
Overall, these results suggest a possible wide spectrum of 
action by TGF-fl as a chemoprotective agent, possibly through 
several different mechanisms. Our results suggest that treat- 
ment with TGF-fl before chemotherapy protects some stem/ 
progenitor cells and increases the number that might then 
be available for restimulation by positive hematopoietic regu- 
lators after chemotherapy. Alternatively, pretreatment with 
positive regulators such as the CSFs, IL-1, IL-3, or SCF fol- 
lowed by TGF-fl might  also be useful  for  increasing  the 
number of regenerating progenitor cells and then protecting 
them from subsequent chemotherapeutic insult. Ultimately, 
the combined use of positive and negative regulators  of he- 
matopoiesis might allow the delivery of more dose-intensive 
chemotherapy with decreased time to recovery, and lead to 
increased antitumor effects in patients with tumors that are 
partially responsive  to chemotherapy. 
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